NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5288512A
(en)
|
1987-12-15 |
1994-02-22 |
The Procter & Gamble Company |
Reduced calorie fats made from triglycerides containing medium and long chain fatty acids
|
NL8800756A
(nl)
|
1988-03-25 |
1989-10-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Genetisch gemanipuleerde plantecellen en planten, alsmede daarvoor bruikbaar recombinant dna.
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
US5457189A
(en)
|
1989-12-04 |
1995-10-10 |
Isis Pharmaceuticals |
Antisense oligonucleotide inhibition of papillomavirus
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
US6034233A
(en)
|
1990-05-04 |
2000-03-07 |
Isis Pharmaceuticals Inc. |
2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
|
IE66205B1
(en)
|
1990-06-14 |
1995-12-13 |
Paul A Bartlett |
Polypeptide analogs
|
US5650489A
(en)
|
1990-07-02 |
1997-07-22 |
The Arizona Board Of Regents |
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
AU650085B2
(en)
|
1990-11-13 |
1994-06-09 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
EP0511116B1
(fr)
*
|
1991-04-26 |
2004-06-16 |
Clonatec S.A. |
Antigènes reconnus par des anticorps de la polyarthrite rhumatoide, leur préparation et leurs applications
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US5474796A
(en)
|
1991-09-04 |
1995-12-12 |
Protogene Laboratories, Inc. |
Method and apparatus for conducting an array of chemical reactions on a support surface
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
EP0538194B1
(fr)
|
1991-10-17 |
1997-06-04 |
Novartis AG |
Nucléosides et oligonucléosides bicycliques, leur procédé de préparation et leurs intermédiaires
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US5605662A
(en)
|
1993-11-01 |
1997-02-25 |
Nanogen, Inc. |
Active programmable electronic devices for molecular biological analysis and diagnostics
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
IL101600A
(en)
|
1992-04-15 |
2000-02-29 |
Yissum Res Dev Co |
Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
CA2125871A1
(fr)
|
1992-10-15 |
1994-04-28 |
Keishi Miwa |
Methode de preparation de proteines d'antigenes d'histocompatibilite de classe ii et materiaux sur lesquels ces proteines sont attachees
|
WO1994026887A1
(fr)
|
1993-05-11 |
1994-11-24 |
The University Of North Carolina At Chapel Hill |
Oligonucleotides antisens combattant l'epissage anormal et leurs procedes d'utilisation
|
EP0804590A1
(fr)
|
1993-05-21 |
1997-11-05 |
Targeted Genetics Corporation |
Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
|
JPH09500378A
(ja)
*
|
1993-07-02 |
1997-01-14 |
リンクス セラピューティクス,インコーポレイティド |
枝分れされそして複雑に結合された高分子構造体の集中的合成
|
CA2170869C
(fr)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Derives amines de nucleosides et d'oligonucleosides
|
US5491084A
(en)
|
1993-09-10 |
1996-02-13 |
The Trustees Of Columbia University In The City Of New York |
Uses of green-fluorescent protein
|
EP0734436B1
(fr)
|
1993-11-30 |
1999-04-14 |
McGILL UNIVERSITY |
Inhibition de la methyltransferase de l'adn
|
US5908779A
(en)
|
1993-12-01 |
1999-06-01 |
University Of Connecticut |
Targeted RNA degradation using nuclear antisense RNA
|
US5925376C1
(en)
*
|
1994-01-10 |
2001-03-20 |
Madalene C Y Heng |
Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
US5593853A
(en)
|
1994-02-09 |
1997-01-14 |
Martek Corporation |
Generation and screening of synthetic drug libraries
|
JPH10501681A
(ja)
|
1994-02-22 |
1998-02-17 |
ダナ−ファーバー キャンサー インスティチュート |
核酸送達システムならびにその合成および使用方法
|
US5902880A
(en)
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US6015880A
(en)
|
1994-03-16 |
2000-01-18 |
California Institute Of Technology |
Method and substrate for performing multiple sequential reactions on a matrix
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
US5525735A
(en)
|
1994-06-22 |
1996-06-11 |
Affymax Technologies Nv |
Methods for synthesizing diverse collections of pyrrolidine compounds
|
US5549974A
(en)
|
1994-06-23 |
1996-08-27 |
Affymax Technologies Nv |
Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
DE19502912A1
(de)
|
1995-01-31 |
1996-08-01 |
Hoechst Ag |
G-Cap Stabilisierte Oligonucleotide
|
KR100258826B1
(ko)
*
|
1995-02-09 |
2000-07-01 |
와트 씨 데이빗 |
Cd28 발현의 조절을 위한 방법 및 조성물
|
US5932556A
(en)
*
|
1995-09-17 |
1999-08-03 |
Tam; Robert C |
Methods and compositions for regulation of CD28 expression
|
PL321711A1
(en)
|
1995-02-09 |
1997-12-22 |
Icn Pharmaceuticals |
Methods of and compositions for controlling the cd28 expression
|
IT1275862B1
(it)
|
1995-03-03 |
1997-10-24 |
Consiglio Nazionale Ricerche |
Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
|
IT1276642B1
(it)
|
1995-03-03 |
1997-11-03 |
Consiglio Nazionale Ricerche |
Trascritto antisenso presente in linfociti b ed oligodeossinucleotidi sintetici utili per inibirne l'azione
|
US5739311A
(en)
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases
|
US5569588A
(en)
|
1995-08-09 |
1996-10-29 |
The Regents Of The University Of California |
Methods for drug screening
|
IT1277025B1
(it)
*
|
1995-12-04 |
1997-11-04 |
Cooperativa Centro Ricerche Po |
Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
|
KR19990082476A
(ko)
|
1996-02-14 |
1999-11-25 |
하우스 한스 루돌프, 긴터 베아트리체 |
당-변형되어 갭이 형성된 올리고뉴클레오티드
|
PT888385E
(pt)
|
1996-03-14 |
2004-01-30 |
Genentech Inc |
Utilizacoes de gdnf e de receptores de gdnf
|
EP0910634A2
(fr)
|
1996-04-17 |
1999-04-28 |
Hoechst Marion Roussel Deutschland GmbH |
Inhibiteurs antisens de l'expression du facteur de croissance endotheliale vasculaire (vegf-vpf)
|
US5786213A
(en)
|
1996-04-18 |
1998-07-28 |
Board Of Regents, The University Of Texas System |
Inhibition of endogenous gastrin expression for treatment of colorectal cancer
|
US5756710A
(en)
|
1996-06-05 |
1998-05-26 |
The Trustees Of Columbia University In City Of New York |
Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US7235653B2
(en)
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6013786A
(en)
|
1997-08-22 |
2000-01-11 |
Hybridon, Inc. |
MDM2-specific antisense oligonucleotides
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
AU9063398A
(en)
|
1997-09-12 |
1999-04-05 |
Exiqon A/S |
Oligonucleotide analogues
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6034883A
(en)
|
1998-01-29 |
2000-03-07 |
Tinney; Charles E. |
Solid state director for beams
|
US6175409B1
(en)
|
1999-04-02 |
2001-01-16 |
Symyx Technologies, Inc. |
Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6221587B1
(en)
|
1998-05-12 |
2001-04-24 |
Isis Pharmceuticals, Inc. |
Identification of molecular interaction sites in RNA for novel drug discovery
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
AU757724B2
(en)
|
1998-05-26 |
2003-03-06 |
Icn Pharmaceuticals, Inc. |
Novel nucleosides having bicyclic sugar moiety
|
US20030139359A1
(en)
|
2001-12-04 |
2003-07-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of phospholipid scramblase 3 expression
|
US6100090A
(en)
|
1999-06-25 |
2000-08-08 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of PI3K p85 expression
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
WO2000027424A2
(fr)
|
1998-11-06 |
2000-05-18 |
Alcon Laboratories, Inc. |
Regulation positive des prostaglandines endogenes visant a baisser la pression intraoculaire
|
US5985663A
(en)
|
1998-11-25 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of interleukin-15 expression
|
ATE533515T1
(de)
|
1999-01-27 |
2011-12-15 |
Coda Therapeutics Inc |
Formulierungen enthaltend antisense nukleotide spezifisch für connexine
|
TR200604211T1
(tr)
|
1999-02-12 |
2007-02-21 |
Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited |
Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları
|
HU227190B1
(en)
|
1999-02-26 |
2010-10-28 |
Univ British Columbia |
Trpm-2 antisense therapy
|
US20040137423A1
(en)
|
1999-03-15 |
2004-07-15 |
Hayden Michael R. |
Compositions and methods for modulating HDL cholesterol and triglyceride levels
|
CA2367955C
(fr)
|
1999-03-15 |
2009-05-19 |
University Of British Columbia |
Methodes et reactifs permettant de moduler les taux de cholesterol
|
DE60045706D1
(de)
|
1999-03-18 |
2011-04-21 |
Exiqon As |
Detektion von genmutationen mittels lna primer
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
ATE332909T1
(de)
|
1999-03-24 |
2006-08-15 |
Exiqon As |
Verbesserte synthese für 2.2.1.öbicyclo- nukleoside
|
WO2000057837A2
(fr)
|
1999-03-26 |
2000-10-05 |
Aventis Pharmaceuticals Products Inc. |
Compositions et procedes agissant sur les taux de cholesterol des lipoproteines de haute densite (hdl) et des apolipoproteines ai, sur les taux de cholesterol des lipoproteines de tres faible densite (vldl) et sur le taux de cholesterol des lipoproteines de faible densite (ldl)
|
EP1171617B1
(fr)
|
1999-04-08 |
2008-02-13 |
Novartis Vaccines and Diagnostics, Inc. |
Stimulation de la reponse immune pour applications dans des vaccins et en therapie genique
|
AU4657500A
(en)
|
1999-04-21 |
2000-11-02 |
Pangene Corporation |
Locked nucleic acid hybrids and methods of use
|
EP1178999B1
(fr)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
Analogues de l-ribo-lna
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
DE19925073C2
(de)
|
1999-06-01 |
2001-07-19 |
Stefan Weiss |
Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
AU781437B2
(en)
|
1999-06-25 |
2005-05-26 |
Serono Genetics Institute S.A. |
A novel BAP28 gene and protein
|
US20040006031A1
(en)
|
2002-07-02 |
2004-01-08 |
Isis Pharmaceuticals Inc. |
Antisense modulation of HMG-CoA reductase expression
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
EP1218411A4
(fr)
|
1999-09-20 |
2004-09-01 |
Millennium Pharm Inc |
Proteines secretees et leurs utilisations
|
EP1700603A3
(fr)
*
|
1999-09-25 |
2007-06-13 |
Coley Pharmaceutical GmbH |
Acides nucléiques immunostimulateurs
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US6986988B2
(en)
|
1999-10-06 |
2006-01-17 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
WO2001025488A2
(fr)
|
1999-10-06 |
2001-04-12 |
Quark Biotech, Inc. |
Procede d'enrichissement en arn messager antisens naturel
|
AU784356B2
(en)
*
|
1999-12-28 |
2006-03-16 |
Bioniche Urology Ip Inc. |
Hyaluronic acid in the treatment of cancer
|
AU2778801A
(en)
|
2000-01-07 |
2001-07-24 |
Baylor University |
Antisense compositions and methods
|
WO2001051490A1
(fr)
|
2000-01-14 |
2001-07-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Analogues nucleosidiques de methanocarba cycloalkyle
|
US6303374B1
(en)
|
2000-01-18 |
2001-10-16 |
Isis Pharmaceuticals Inc. |
Antisense modulation of caspase 3 expression
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
JP2001247459A
(ja)
|
2000-03-03 |
2001-09-11 |
Oakland Uniservices Ltd |
癌の組み合わせ療法
|
US6936467B2
(en)
|
2000-03-27 |
2005-08-30 |
University Of Delaware |
Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
|
KR20030003240A
(ko)
|
2000-03-27 |
2003-01-09 |
유니버시티 오브 델라웨어 |
개질된 단일 가닥 올리고뉴클레오티드를 이용한 표적염색체 게놈 변경법
|
US7402434B2
(en)
|
2000-05-08 |
2008-07-22 |
Newman Stuart A |
Splice choice antagonists as therapeutic agents
|
JP2004530420A
(ja)
|
2000-06-29 |
2004-10-07 |
ファーマ パシフィック プロプライエタリー リミテッド |
インターフェロン−α誘導性遺伝子
|
WO2002009700A1
(fr)
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Traitement combine contre le cancer
|
US7053199B2
(en)
|
2000-08-29 |
2006-05-30 |
Takeshi Imanishi |
Nucleoside analogs and oligonucleotide derivatives containing these analogs
|
DE50113568D1
(de)
|
2000-09-02 |
2008-03-20 |
Gruenenthal Gmbh |
Antisense oligonukleotide gegen vr 1
|
US6444464B1
(en)
|
2000-09-08 |
2002-09-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of E2F transcription factor 2 expression
|
AU2001289085A1
(en)
|
2000-09-20 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of flip-c expression
|
WO2002031141A2
(fr)
|
2000-10-13 |
2002-04-18 |
Institut De Cardiologie De Montreal |
Oligonucleotide antisens dirige vers des genes de recepteur du facteur de croissance endotheliale vasculaire (vegf) mammifere et ses utilisations
|
US20030228618A1
(en)
|
2000-11-24 |
2003-12-11 |
Erez Levanon |
Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same
|
US20050222029A1
(en)
|
2001-01-04 |
2005-10-06 |
Myriad Genetics, Incorporated |
Compositions and methods for treating diseases
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
WO2002068470A2
(fr)
|
2001-02-26 |
2002-09-06 |
Pharma Pacific Pty Ltd |
Gene induit par l'interferon alpha
|
US20020147165A1
(en)
|
2001-02-22 |
2002-10-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of calreticulin expression
|
WO2002067996A2
(fr)
|
2001-02-24 |
2002-09-06 |
Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh |
Agent servant a combattre la douleur localement
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
AUPR497101A0
(en)
|
2001-05-14 |
2001-06-07 |
Queensland University Of Technology |
Polynucleotides and polypeptides linked to cancer and/or tumorigenesi
|
WO2005014811A2
(fr)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
Inhibition a mediation par interference arn de l'expression du gene xiap au moyen d'acide nucleique interferent court
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
US7053195B1
(en)
|
2001-06-12 |
2006-05-30 |
Syngenta Participatious Ag |
Locked nucleic acid containing heteropolymers and related methods
|
CA2453183C
(fr)
|
2001-07-12 |
2016-05-10 |
University Of Massachusetts |
Production in vivo de petits arn d'interference qui regulent le silencage genique
|
US7153954B2
(en)
|
2001-07-12 |
2006-12-26 |
Santaris Pharma A/S |
Method for preparation of LNA phosphoramidites
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
US20040214766A1
(en)
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
ES2258173T3
(es)
|
2001-10-10 |
2006-08-16 |
Societe Des Produits Nestle S.A. |
Planta de cafe con actividad alfa-d-galactosidasa reducida.
|
AR037699A1
(es)
|
2001-12-04 |
2004-12-01 |
Monsanto Technology Llc |
Maiz transgenico con fenotipo mejorado
|
US7125982B1
(en)
|
2001-12-05 |
2006-10-24 |
Frayne Consultants |
Microbial production of nuclease resistant DNA, RNA, and oligo mixtures
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
CA2365811A1
(fr)
|
2001-12-21 |
2003-06-21 |
Institut De Cardiologie |
Nouvelle therapie genique utilisant la strategie anti-sens pour les recepteurs estrogeniques (er .alpha. et/ou er .beta.) afin d'optimiser la regeneration vasculaire et la cardioprotection a la suite d'une lesion va sculaire
|
KR20030056538A
(ko)
|
2001-12-28 |
2003-07-04 |
주식회사 웰진 |
리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
|
US20030191075A1
(en)
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
AU2003212729A1
(en)
|
2002-02-25 |
2003-09-09 |
Gunnar Norstedt |
Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
|
EP1483280B1
(fr)
|
2002-03-08 |
2012-10-24 |
Glen Research Corporation |
Base azotee fluorescente et nucleosides comprenant cette base
|
GB2386836B
(en)
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
US7169916B2
(en)
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
US20050215504A1
(en)
|
2002-04-02 |
2005-09-29 |
Bennett C F |
Antisense modulation of sterol regulatory element-binding protein-1 expression
|
SI2264172T1
(sl)
|
2002-04-05 |
2017-12-29 |
Roche Innovation Center Copenhagen A/S |
Oligomerne spojine za modulacijo izražanja HIF-1alfa
|
US7670612B2
(en)
*
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
US6808906B2
(en)
|
2002-05-08 |
2004-10-26 |
Rigel Pharmaceuticals, Inc. |
Directionally cloned random cDNA expression vector libraries, compositions and methods of use
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US20040033480A1
(en)
|
2002-08-15 |
2004-02-19 |
Wong Norman C.W. |
Use of resveratrol to regulate expression of apolipoprotein A1
|
EP1555870A4
(fr)
|
2002-09-10 |
2006-11-02 |
Samuel Roberts Noble Found Inc |
Procedes et compositions permettant de generer des produits nutraceutiques contenant des flavonoides et des isoflavonoides
|
JP2006500070A
(ja)
|
2002-09-25 |
2006-01-05 |
ファルマシア・コーポレーション |
ファルネソイドx受容体発現のアンチセンス調節
|
JP2006500066A
(ja)
*
|
2002-09-25 |
2006-01-05 |
ファルマシア・コーポレーション |
ミクロソームのプロスタグランジンe2シンターゼ発現のアンチセンス調節
|
EP2272958A1
(fr)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation de l'expression de la boîte Forkhead O1A
|
US20040152651A1
(en)
|
2002-11-01 |
2004-08-05 |
Rana Tariq M. |
Regulation of transcription elongation factors
|
EP1562970A4
(fr)
|
2002-11-01 |
2006-04-12 |
Univ Pennsylvania |
Compositions et procedes destines a l'inhibition par arnsi des hif-1 alpha
|
GB2394658A
(en)
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
WO2004041889A2
(fr)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
|
WO2004044136A2
(fr)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
|
US20060009410A1
(en)
|
2002-11-13 |
2006-01-12 |
Crooke Rosanne M |
Effects of apolipoprotein B inhibition on gene expression profiles in animals
|
DK2141233T3
(en)
|
2002-11-18 |
2017-01-09 |
Roche Innovation Ct Copenhagen As |
Antisense Design
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7790867B2
(en)
*
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7339051B2
(en)
|
2003-04-28 |
2008-03-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
|
CA2540692C
(fr)
|
2003-06-02 |
2013-05-28 |
Isis Pharmaceuticals, Inc. |
Synthese d'oligonucleotides au moyen de solvants alternatifs
|
JP4579911B2
(ja)
|
2003-06-03 |
2010-11-10 |
アイシス・ファーマシューティカルズ・インコーポレイテッド |
スルビビン発現の調節
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP2182063A3
(fr)
|
2003-09-18 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Modulation de l'expression EIF4E
|
EP1687410A4
(fr)
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
Oligonucleotides antisens optimises pour cibler le rein
|
EP1675948A2
(fr)
|
2003-10-23 |
2006-07-05 |
Sirna Therapeutics, Inc. |
Traitement medie par interference arn de la maladie de parkinson au moyen d'un petit acide nucleique interferent (sina)
|
US20050203130A1
(en)
*
|
2003-12-02 |
2005-09-15 |
Erik Buntinx |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
TWI240094B
(en)
|
2003-12-11 |
2005-09-21 |
Univ Nat Cheng Kung |
Gradient refractive-index plastic rod and method for making the same
|
ATE467679T1
(de)
|
2003-12-23 |
2010-05-15 |
Santaris Pharma As |
Oligomere verbindungen zur modulation von bcl-2
|
JP4801802B2
(ja)
|
2004-01-12 |
2011-10-26 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
特定の選択的な電気信号および電磁信号によって生成される電場の印加を介して骨細胞における骨形成タンパク質(bmp)遺伝子発現を上方制御するシステムおよび方法
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
GB0403041D0
(en)
|
2004-02-11 |
2004-03-17 |
Milner Anne J |
Induction of apoptosis
|
EP1566202A1
(fr)
|
2004-02-23 |
2005-08-24 |
Sahltech I Göteborg AB |
Utilisation d'agonistes de la resistine pour le traitement de l'arthrite rheumatoide
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7297786B2
(en)
|
2004-07-09 |
2007-11-20 |
University Of Iowa Research Foundation |
RNA interference in respiratory epitheial cells
|
WO2006023880A2
(fr)
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Composes et procedes permettant de caracteriser les oligonucleotides
|
BRPI0515726A8
(pt)
|
2004-11-09 |
2017-09-12 |
Santaris Pharma As |
Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
|
US7220549B2
(en)
|
2004-12-30 |
2007-05-22 |
Helicos Biosciences Corporation |
Stabilizing a nucleic acid for nucleic acid sequencing
|
JP5116107B2
(ja)
|
2005-06-27 |
2013-01-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
HIF−1のRNAi調節及びその治療的利用
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
KR100659138B1
(ko)
*
|
2005-09-16 |
2006-12-19 |
(주)아모레퍼시픽 |
유효성분으로 갈로카테킨 갈레이트를 함유하는 보습용피부외용제 조성물
|
CN101365801B
(zh)
|
2005-10-28 |
2013-03-27 |
阿尔尼拉姆医药品有限公司 |
抑制亨廷顿基因表达的组合物和方法
|
CA2626584A1
(fr)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes pour inhiber l'expression du gene nav1.8
|
EP2641970B1
(fr)
|
2005-11-17 |
2014-12-24 |
Board of Regents, The University of Texas System |
Modulation de l'expression génétique par oligomères ciblés à l'ADN chromosomique
|
EP1957109A2
(fr)
*
|
2005-12-02 |
2008-08-20 |
Sirtris Pharmaceuticals, Inc. |
Modulateurs de kinases de type cdc2 (clks) et leurs procédés d'utilisation
|
CN101378764A
(zh)
|
2005-12-09 |
2009-03-04 |
贝勒研究院 |
通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
|
CN100356377C
(zh)
|
2005-12-20 |
2007-12-19 |
无锡永中科技有限公司 |
文档显示方法
|
WO2007071824A1
(fr)
|
2005-12-20 |
2007-06-28 |
Oy Jurilab Ltd |
Nouveaux gènes et marqueurs associés au cholestérol lipoprotéine haute densité (hdl-c)
|
CN101437933B
(zh)
*
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
作为药物靶标的天然反义和非编码的rna转录物
|
AU2007211080B9
(en)
|
2006-01-27 |
2012-05-03 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
CA2647728C
(fr)
|
2006-03-31 |
2014-12-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes destinees a inhiber l'expression du gene eg5
|
DK2458006T3
(en)
|
2006-05-05 |
2018-08-27 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating ApoB Expression.
|
CA2915441A1
(fr)
|
2006-05-11 |
2007-11-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procedes d'inhibition de l'expression du gene pcsk9
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
WO2007134181A2
(fr)
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Analogues d'acides nucléiques bicycliques modifiés en 5'
|
EP1867338A1
(fr)
|
2006-05-30 |
2007-12-19 |
Université Libre De Bruxelles |
Composition pharmaceutique comprenant des apolipoprotéines
|
WO2008057556A2
(fr)
|
2006-11-06 |
2008-05-15 |
Beth Israel Deaconess Medical Center |
Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription ese-1 et pour traiter les maladies associées au facteur de transcription ese-1
|
WO2008066672A2
(fr)
|
2006-11-06 |
2008-06-05 |
Beth Israel Deaconess Medical Center |
Identification et utilisation de petites molécules pour moduler une fonction de facteur de transcription et pour traiter des maladies associées à un facteur de transcription
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
EP2121939B1
(fr)
|
2007-01-19 |
2013-12-04 |
Plant Bioscience Limited |
Procédés destinés à moduler les voies de méthylation de l'adn dirigé par l'arn et les petits arni
|
WO2008124660A2
(fr)
|
2007-04-06 |
2008-10-16 |
The Johns Hopkins University |
Procédés et compositions pour le traitement du cancer
|
US20080293142A1
(en)
|
2007-04-19 |
2008-11-27 |
The Board Of Regents For Oklahoma State University |
Multiple shRNA Expression Vectors and Methods of Construction
|
US9040774B2
(en)
|
2008-07-01 |
2015-05-26 |
Monsanto Technology Llc |
Recombinant DNA constructs encoding ribonuclease cleavage blockers and methods for modulating expression of a target gene
|
US8153606B2
(en)
|
2008-10-03 |
2012-04-10 |
Opko Curna, Llc |
Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
|
EP2177615A1
(fr)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales
|
US8606289B2
(en)
|
2008-11-10 |
2013-12-10 |
Qualcomm Incorporated |
Power headroom-sensitive scheduling
|
EP2358382A2
(fr)
|
2008-11-22 |
2011-08-24 |
The University of Bristol |
NOUVELLES UTILISATIONS DE VEGFxxxB
|
KR101802540B1
(ko)
|
2009-09-25 |
2017-11-28 |
큐알엔에이, 인크. |
Flg의 발현 및 활성을 조절함으로써 필라그린(flg)에 관련된 질환의 치료
|